PRGO — Perrigo Company plc

Summary of Perrigo (PRGO) Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Q3 2025 EPS: $0.80, up $0.01 year-over-year.
• Year-to-Date EPS: $1.97, up 21% (27% organically).
• Organic Net Sales: Declined 4.4% in Q3 and 1.7% year-to-date, impacted by soft OTC consumption and businesses under review (Infant Formula and Oral Care).
• Gross Profit: $417 million in Q3, down $30 million year-over-year; gross margin declined 110 basis points.
• Operating Income: $173 million in Q3, down 4.9%; year-to-date operating income increased $41 million to $455 million.
• Operating Cash Flow: $52 million in Q3; year-to-date cash flow at $63 million.
• Debt to Adjusted EBITDA: Expected to rise to approximately 3.8x from a prior target of 3.5x due to updated net sales expectations.

2. Strategic Updates and Business Highlights

• Three-S Plan: Focus on Stabilizing, Streamlining, and Strengthening the business continues to guide Perrigo's actions.
• Market Share Gains: Perrigo has gained share in U.S. OTC store brands for six consecutive months and in key European brands for five months, despite overall market declines.
• Project Energize: Achieved $163 million in gross annual savings, exceeding initial targets.
• Divestitures: The sale of the Dermacosmetics business is on track to close in Q1 2026; a strategic review of the Infant Formula business is underway.
• Innovation and Brand Building: Investments are being made to enhance brand capabilities and consumer insights.

3. Forward Guidance and Outlook

• Revised 2025 Outlook: Organic net sales are now expected to decline by 2% to 2.5% due to softer OTC consumption and slower recovery in Infant Formula.
• Expected EPS for 2025: Revised guidance of $2.70 to $2.80, representing 5% to 9% growth compared to 2024.
• Q4 Expectations: Anticipated organic growth in global OTC business to be flat to 1%, with margins expected to be lower than prior year levels.

4. Bad News, Challenges, or Points of Concern

• Soft Market Conditions: OTC category consumption has declined significantly, with U.S. OTC volume down 3.2% and European growth at only 0.6%.
• Infant Formula Challenges: Share recovery is slower than expected, with current share at approximately 16%. Competitive pressures from imported formulas are impacting growth.
• Operational Pressures: Gross margin pressures due to sales deleverage and a shift towards lower-margin store brands.
• Investment Pause: The previously announced $240 million investment in Infant Formula has been paused pending the strategic review.

5. Notable Q&A Insights

• Infant Formula Dynamics: Retail destocking and competitive pressures have contributed to slower share growth; new SKUs are underperforming due to shelf space issues.
• OTC Consumption Trends: Consumption has been volatile and unpredictable, with a potential normalization expected in 2026.
• Reinvestment Plans: While maintaining focus on deleveraging and dividends, there may be increased spending in high-performing areas, particularly in U.S. store brands and international markets.
• Future EBITDA Growth: Expectations for flat to small percentage growth in 2026, with ongoing share gains anticipated despite headwinds from competitive pressures and market dynamics.

This summary encapsulates the key points from Perrigo's Q3 2025 earnings call, highlighting both the company's achievements and the challenges it faces in a fluctuating market environment.